Sunitinib Therapy for Melanoma Patients with <i>KIT</i> Mutations

Abstract

Sunitinib may have activity in patients with melanoma and KIT mutations; more study is needed. KIT mutations may represent an adverse prognostic factor in metastatic melanoma.